SEC
SlamSEC
SearchBrowseEarnings

Organogenesis Holdings Inc.

Nasdaq:ORGO
Pharmaceutical Preparations·CANTON, MA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Organogenesis is the phase of embryonic development that starts at the end of gastrulation and continues until birth. During organogenesis, the three germ layers formed from gastrulation form the tissues and internal organs of the organism.

CEO
Gillheeney Gary S.
CFO
Francisco David
Revenue
$433.1M
-3.9% YoY
FY 2025
Adj. EBITDA
$23.0M
5.3% margin
FY 2025
Net Income
$4.9M
1.1% margin
FY 2025
EPS (Diluted)
$0.04
FY 2025
Stock Price
$2.72
-1.4%
2026-03-10
52W Range
$2.61 – $7.08
P/E Ratio
68.0x
Market Cap
$349.9M
Cash
$135.6M
FY 2025
Total Debt
$52.2M
FY 2019
Net Cash
$83.4M
FY 2019
Enterprise Value
$266.5M
Debt / EBITDA
-3.6x
FY 2025
EV / EBITDA
11.6x
Employees
—